Description: Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
Home Page: www.vivabiotech.com.cn
No.735, Ziping Road
Shanghai,
201318
China
Phone:
86 21 6089 3288
Officers
Name | Title |
---|---|
Dr. Chen Cheney Mao Ph.D. | Chairman & CEO |
Dr. Delin Ren Ph.D. | Pres & Exec. Director |
Mr. Zheren Wang C.F.A. | Chief Financial Officer |
Mr. Xueheng Cheng Ph.D. | Chief Technology Officer |
Dr. Zhixiong Ye Ph.D. | Chief Scientific Officer |
Mr. Ying Wu M.B.A. | Exec. VP & Exec. Director |
Mr. Han Dai Ph.D. | CIO & Head of Viva BioInnovator |
Mr. Jianhua Cai Ph.D. | Sr. VP |
Jianguo Ma Ph.D. | Sr. VP & CEO of Langhua Pharmaceutical |
Mr. Xianyong Bu Ph.D. | Sr. VP |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
Forward PE: | 0 |
---|---|
Trailing PE: | 20.7778 |
Price-to-Book MRQ: | 0.8386 |
Price-to-Sales TTM: | 1.5331 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 2309 |